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ABSTRACT 
BACKGROUND:  Endothelial progenitor cells (EPCs) might be useful in the man- 
agement of coronary artery disease (CAD). 
OBJECT IVE:  The aim of this study was to investigate the effects of xuezhikang, 
an extract of Chinese red yeast rice, on the proliferation and adhesion capacity of EPCs 
from the peripheral blood of patients with stable CAD. 
METHODS:  Mononuclear cells from 20 Chinese patients (14 men, 6 women; 
mean [SD] age, 64.5 [2.8] years [range, 60-69 years]) were isolated using density- 
gradient centrifugation. After 4 days in culture, the attached cells were treated with 
different concentrations of xuezhikang (50, 125, 250, and 500 ng/mL; 20 samples/ 
group), atorvastatin (10 ng/mL; n = 20), or phosphate-buffered saline (control, n = 20) 
for 3 days. Cells that were positive for 1,Y-dioctadecyl-3,3,3',3'-tetramethylindocarbo- 
cyanine-labeled acetylated low-density lipoprotein and lectin were defined as EPCs. 
They were counted by 2 independent investigators in _>4 randomly selected high- 
power fields per well. EPCs were then treated and adherent cells were counted by the 
independent investigators who were blinded to study drug administration. 
RESULTS:  The mean (SD) number of cultured EPCs in the xuezhikang 50-, 
125-, 250-, and 500-ng/mL groups (205 [28], 244 [31], 283 [42], and 334 [43] cells, 
respectively; all, P < 0.001) was significantly increased in a dose-dependent manner 
compared with the control group (167 [36] cells). The adhesion capacity of the EPCs 
was significantly greater in the 4 xuezhikang roups (51 [9], 62 [10], 71 [11], and 
83 [12] cells; all, P < 0.001) when compared with that of the control group (41 
[7] cells). Both the number of EPCs (327 [49] cells) and the number of adhesive EPCs 
(84 [15] cells) in the atorvastatin group were also significantly increased compared 
with the control group (both, P < 0.001); however, these increases were not signifi- 
cantly different from those in the xuezhikang 500-ng/mL group. 
CONCLUStONS:  Xuezhikang was associated with significantly enhanced prolif- 
eration and adhesion capacity of EPCs derived from the peripheral blood of these 
patients with stable CAD. These effects were not significantly different between xuezhi- 
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kang and atorvastatin. (Curr Ther Res Clin Exp. 2008;69:252-259) © 2008 Excerpta 
Medica Inc. 
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INTRODUCTION 
Bone marrow-derived ndothelial progenitor cells (EPCs) are capable of differentiat- 
ing into endothelial cells in ischemic tissue, contributing to neovascularization and 
endothelial function.l-3 There is growing evidence that EPCs isolated from peripheral 
blood migrate to the ischemic sites and disrupt endothelium. 4 In experimental 
models of myocardial infarction, injection of ex vivo-expanded EPCs significantly 
improved blood flow and cardiac function and reduced left ventricular scarring. 5,6 In 
addition, several small clinical trials have found that EPCs acquired from bone mar- 
row or peripheral blood enhanced the blood supply of the ischemic tissues in the limbs 
and the heart. 7,8 
Increasing the number or the adhesion capacity of circulating EPCs may be a useful 
strategy for managing coronary artery disease (CAD). Several studies 9-11 found that 
statins significantly increased the number of circulating EPCs and their adhesion 
capacity. 
Xuezhikang isan extract of Chinese red yeast rice. In a clinical triall2 of 83 patients 
with hyperlipidemia, oral xuezhikang supplements (2.4 g/d) administered for 12 weeks 
reduced concentrations of serum triglycerides, total cholesterol, and low-density lipo- 
protein cholesterol by up to 30%. Xuezhikang is also associated with improved pre- 
prandial and postprandial endothelial function through its potent anti-inflammatory 
and lipid-lowering effects. 13 
In the present study, we investigated the effect of xuezhikang (WBL Peking Uni- 
versity Biotech Co., Ltd., Beijing, China) on the proliferation and adhesion capaci- 
ty of EPCs isolated from the peripheral blood of patients with stable CAD. 
PAT IENTS AND METHODS 
PAT IENT CHARACTERIST ICS  
Between January and May 2006, 32 Chinese patients were approached toparticipate 
in the study at the Department ofCardiology, Liaocheng People's Hospital (Shandong 
Province, China). After the initial screening, 20 patients (14 men, 6 women; mean [SD] 
age, 64.5 [2.8] years [range, 60-69 years]) with angiographically documented CAD 
and clinical evidence of stable angina pectoris were enrolled in the study. None of the 
patients had been treated with a statin in the 4 weeks immediately preceding the study. 
Patients with unstable angina or myocardial infarction in the past 3 months were 
excluded from the study. Patients with concomitant inflammatory or malignant dis- 
eases were also excluded. 
The study was approved by the institutional review board of Liaocheng Clinical 
School of Taishan Medical College, Shandong Province, China. Written informed con- 
sent was obtained from all participants. 
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ENDOTHEL IAL  PROGENITOR CELL  CULTURE 
Mononuclear cells were isolated from the peripheral blood of patients by density- 
gradient centrifugation using previously described methods. 6,9 Immediately after 
isolation, mononuclear cells were plated on 24-well culture dishes coated with 
human fibronectin (Gibico, Grand Island, New York) and maintained in endothe- 
lial basal medium (EBM) (Clonetics, Lonza, Inc., Allendale, New Jersey). This 
medium was supplemented with 20% fetal calf serum, 50 ng/mL vascular 
endothelial growth factor (Sigma-Aldrich Corp., St. Louis, Missouri), 50 ng/mL 
stem cell factor (Sigma-Aldrich Corp.), 100 U/mL benzylpenicillin, and 100 U/mL 
streptomycin. 
After 4 days in culture, nonadherent cells were removed by a thorough washing 
with phosphate-buffered saline (PBS). Adherent cells were maintained and treated 
with different concentrations of xuezhikang (50, 125, 250, or 500 ng/mL), atorva- 
statin* (10 ng/mL), or PBS (control group) for 3 days. 
CHARACTERIZAT ION OF EP ITHEL IAL  PROGENITOR CELLS  
The investigators reviewing the characterization f EPCs were blinded to the 
group allocation. To detect the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo- 
carbocyanine-labeled acetylated low-density lipoprotein (DiLDL) (Molecular 
Probes, Invitrogen Corporation, Carlsbad, California), adherent cells were incu- 
bated with DiLDL (2.4 pg/mL) at 37°C for 1 hour. Cells were then fixed with 
2% paraformaldehyde for 10 minutes and incubated with Ulex europaeus agglu- 
tinin I conjugated with fluorescein isothiocyanate (FITC) (FITC-lectin, 10 pg/mL) 
(Sigma-Aldrich Corp.) at 37°C for another hour. Cells were then observed with 
an inverted fluorescent microscope (Olympus Corp., Tokyo, Japan). Cells that 
were positive for both DiLDL and lectin were defined as EPCs. They were count- 
ed by 2 independent investigators in _>4 randomly selected high-power fields per 
well. 
CELL  ADHESION ASSAY 
After 7 days, EPCs were washed and gently detached with 0.1% trypsin in PBS. 
EPCs were then spun, resuspended in EBM-2 with 5% fetal calf serum, and counted. 
The same numbers of EPCs were replated onto fibronectin-coated culture dishes and 
incubated for 30 minutes at 37°C. Adherent cells were counted by independent inves- 
tigators who were blinded to the treatment. In each blood sample, ->4 randomly 
selected high-power fields were counted per well. 
STATIST ICAL  ANALYS IS  
Data were expressed as mean (SD). Comparisons of numbers of cells between 
groups were performed using the Student test. P < 0.05 was considered statistically 
significant. 
*Trademark: ® Lipitor (Pfizer Inc., Dalian, China). 
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RESULTS 
MORPHOLOGY AND IDENTIF ICAT ION OF EP ITHEL IAL  PROGENITOR CELLS  
The initially seeded cells were round. The EPC colonies with spindle-shaped cells 
radiating around the round cells in the core were observed after 4 to 5 days of cul- 
ture. EPCs were identified as positive for uptake of both DiLDL and lectin in all 
samples. 
EFFECT OF XUEZHIKANG ON EP ITHEL IAL  PROGENITOR CELL  PROL IFERAT ION 
After 7 days, the mean number of EPCs was significantly increased in the xuezhikang- 
treated groups (50, 125, 250, 500 ng/mL) (205 [28], 244 [31], 283 [42], 334 
[43] cells, respectively) compared with the control group (167 [36] cells; all, P < 
0.001). The number of EPCs was also significantly increased in the atorvastatin-treated 
group (327 [49] cells) compared with the control group (P < 0.001). The mean 
number of EPCs in the 500-ng/mL xuezhikang roup was not significantly different 
from the atorvastatin group (Table). However, the mean number of EPCs in other 
xuezhikang groups was significantly ess than that observed in the atorvastatin group 
(all, P < 0.01). 
EFFECTS OF  XUEZHIKANG ON EP ITHEL IAL  PROGENITOR CELL  ADHESION 
CAPACITY  
Compared with the control group (41 [7] cells), the mean number of adhesive EPCs 
was significantly higher in the xuezhikang-treated groups (50, 125,250, 500 ng/mL) 
(51 [9], 62 [10], 71 [11], 83 [12] cells, respectively; all, P < 0.001), with a peak in 
the 500-ng/mL group (2-fold increase). A significantly higher cell count was also 
observed in the atorvastatin group (84 [15] cells) compared with the control group 
(P < 0.001). No significant difference in the number of adhesive EPCs was found 
between the 500-ng/mL xuezhikang group and the atorvastatin group, but the num- 
ber of adhesive cells in other xuezhikang roups was significantly less than in the 
atorvastatin group (P < 0.01) (Table). 
DISCUSSION 
A search of English-language articles in MEDLINE and PubMed (1980-2007) 
using the combined search terms xuezhikang and EPCs found that this was the first 
published study to suggest hat xuezhikang exerts a dose-dependent effect on the 
proliferation and adhesion capacity of EPCs in patients with stable CAD. This 
study also found that atorvastatin was associated with increased EPCs and improve- 
ment of adhesive capacity in a manner similar to the highest dose of xuezhikang 
(500 ng/mL). 
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) 
have been developed as lipid-lowering drugs and have been reported to reduce mor- 
bidity and mortality in patients with CAD. 14 There is growing evidence that the 
beneficial effects of statins on CAD outcomes may go beyond the lipid-lowering 
actions. Dimmeler et al 9 found that statins potently augmented EPC differentiation 
in mononuclear cells and CD34 + hematopoietic stem ceils isolated from peripheral 
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blood. Assmus et a115 reported that atorvastatin dose-dependently enhanced the inhi- 
bition of EPC senescence. Atorvastatin also induced EPC proliferation i vitro, which 
might lead to improvement in the functional activity of EPCs.15 Furthermore, statins 
were found to facilitate the migration and potency of EPCs to form vessel structures 
and to contribute to vasculogenesis. 16 
The mechanisms mediating the effects ofstatins on EPCs remain to be determined. 
Phosphatidylinositol 3-kinase (PI3K)/Akt was found to mediate the effect of statins 
on EPCs. 9 Activation of the PI3K/Akt pathway by statins may have multiple protec- 
tive effects on EPCs, including an increase in numbers, inhibition of apoptosis, 
improvement of functional activity, and the prevention of senescence. :5 Also, migra- 
tion and tube formation of EPCs may be blocked by PI3K/Akt inhibitors, indicating 
that the effects of statins on EPCs involve the PI3K/Akt signaling pathway. 9,16 Apart 
from the PI3K/Akt pathway, increased availability of endothelial nitric oxide is 
pivotal for statin-induced improvement in EPC mobilization and myocardial neo- 
vascularization after myocardial infarction. 17 
The effect of xuezhikang on EPCs was assessed from 2 perspectives in the present 
study. First, xuezhikang was associated with a dose-dependent increase in the number 
of cultured EPCs. At the highest dose (500 ng/mL) of xuezhikang, the increase in the 
mean number of EPCs was not significantly different from the increase after atorva- 
statin treatment. Second, the function of the EPCs was assessed by measuring the 
mean number of adhesive cells after treatment. Several studies found that migration 
of EPCs to the sites of ischemia nd the resultant neovascularization nvolved several 
key processes, including adhesion to endothelial cells, incorporation i to capillaries, 
and transendothelial migration into extravascular space. :8,19 Adhesion to fibronectin, 
cultured endothelial cells, and cardiomyocytes is critical for EPCs to participate in 
trafficking in ischemic muscle. 18,2° In the present study, xuezhikang was associated 
with a 2-fold increase in the mean number of adhesive EPCs, indicating enhancement 
of the adhesion capacity. The study also found that atorvastatin 10 ng/mL was associ- 
ated with a 2-fold increase in the adhesion capacity of EPCs. 
A potential limitation of this study was that xuezhikang is not a single chemical 
entity: it contains statin-like compounds that inhibit the actions of HMG-CoA re- 
ductase, fatty acids, and isoflavones.12 It has lipid-lowering as well as anti-inflammatory 
actions. 13 Therefore, although xuezhikang and atorvastatin were associated with similar 
results in the increase in the number and adhesion capacity of EPCs compared with the 
control group, the mechanisms resulting in these outcomes may be different and require 
further investigation. Another limitation of the study was the small sample size. 
Further studies are required to investigate whether the effects of xuezhikang on 
cultured EPCs are also present in vivo. Whether the beneficial effects of xuezhikang 
on the proliferation and functional activities of EPCs can be translated into improve- 
ment in the clinical outcomes of CAD also needs to be further investigated. 
CONCLUSIONS 
The present study found that at a high dose, xuezhikang was not statistically different 
from atorvastatin i  increasing the proliferation and adhesive capacity of EPCs from 
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peripheral blood in these patients with stable CAD. These findings provide further 
explanation of the previously reported beneficial effects ofxuezhikang on the endothe- 
lial function in patients with CAD. 
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